Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
The human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 was produced in large-scale microcarrier cultures of Vero cells, using a system involving coinfection with two recombinant vaccinia viruses. The immunogenicity of this material was studied in conjunction with a number of different adjuvant formulations, and chimpanzees were then immunized with gp160 in conjunction with Al(OH)3, Al(OH)3 and sodium deoxycholate, and a lipid-based adjuvant. The Al(OH)3-gp160 vaccine formulation elicited very poor immune responses in two chimpanzees, and these animals were further immunized with gp160 in conjunction with a lipid-based adjuvant. Immunization with the latter formulation lead to induction of high-titer neutralizing antibodies, and, following challenge with HIV-1, one chimpanzee demonstrated no evidence of virus infection over a period of 3 years. The second chimpanzee, which had previously been infected with non-A, non-B hepatitis, and two animals immunized with gp160 with Al(OH)3 and deoxycholate were not protected against challenge.
Barrett
N
N
Biomedical Research Center, Immuno AG, Orth/Donau, Austria.
Eder
G
G
Dorner
F
F
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D015686:Gene Products, env / Q000276:immunology*; D006041:Goats; D015483:HIV Antibodies / Q000096:biosynthesis; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D009500:Neutralization Tests; D002679:Pan troglodytes; D011498:Protein Precursors / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D014616:Vaccinia virus
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015686:Gene Products, env; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D014614:Vaccines, Synthetic